Table 2 Impact of 2v, 4v and 9v vaccine based on the ICC cases infected with vaccine targeted genotype

Cases infected with genotypes targeted by 2v vaccine(HPV16/18)

152 (82.16%)

181 (97.83%)

89.99%

Cases infected with genotypes targeted by 4v vaccine(HPV16/18/6/11)

152 (82.6%)

183 (98.91%)

91.65%

Cases infected with genotypes targeted by 9v vaccine(HPV16/18/6/11/31/33/45/52/58)

156 (84.32%)

185 (100%)

92.16%

Absolute additional impact of 4v vaccine (compared with 2v vaccine)

-

1.08%

1.08%

Relative additional impact of 4v vaccine (compared with 2v vaccine)

-

1.09%

1.09%

Absolute additional impact of 9v vaccine(compared with 2v vaccine)

2.1%

2.16%

2.16%

Relative additional impact of 9v (compared with 2v vaccine)

2.4%

2.16%

2.28%

Absolute additional impact of 9v vaccine (compared with 4v vaccine)

2.1%

2.16%

2.16%

Relative additional impact of 9v vaccine (compared with 4v vaccine)

1.08%

1.09%

1.085%